{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T07:25:08Z","timestamp":1794468308167,"version":"4.9.1"},"reference-count":28,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2014,12,19]],"date-time":"2014-12-19T00:00:00Z","timestamp":1418947200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100013515","name":"Hong Kong Cancer Fund","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100013515","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003808","name":"Hong Kong Hospital Authority","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003808","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2015,4,15]]},"abstract":"<jats:sec><jats:title>BACKGROUND<\/jats:title><jats:p>A current recommendation for locoregionally advanced nasopharyngeal carcinoma (NPC) is conventional fractionated radiotherapy with concurrent cisplatin plus adjuvant cisplatin and fluorouracil (PF). In this randomized trial, the authors evaluated the potential therapeutic benefit from changing to an induction\u2010concurrent chemotherapy sequence, replacing fluorouracil with oral capecitabine, and\/or using accelerated rather than conventional radiotherapy fractionation.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p>Patients with stage III through IVB, nonkeratinizing NPC were randomly allocated to 1 of 6 treatment arms. The protocol was amended in 2009 to permit confining randomization to the conventional fractionation arms. The primary endpoint was progression\u2010free survival. Secondary endpoints included overall survival and safety.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>In total, 803 patients were accrued, and 706 patients were randomly allocated to all 6 treatment arms. Comparisons of induction PF versus adjuvant PF did not indicate a significant improvement. Unadjusted comparisons of induction cisplatin and capecitabine (PX) versus adjuvant PF indicated a favorable trend in progression\u2010free survival for the conventional fractionation arm (<jats:italic>P<\/jats:italic>\u2009=\u2009.045); analyses that were adjusted for other significant factors and fractionation reflected a significant reduction in the hazards of disease progression (hazard ratio [HR], 0.54; 95% confidence interval [CI], 0.36\u20100.80) and death (HR, 0.42; 95% CI, 0.25\u20100.70). Unadjusted comparisons of induction sequences versus adjuvant sequences did not reach statistical significance, but adjusted comparisons indicated favorable improvements by induction sequence. Comparisons of induction PX versus induction PF revealed fewer toxicities (neutropenia and electrolyte disturbance), unadjusted comparisons of efficacy were statistically insignificant, but adjusted analyses indicated that induction PX had a lower hazard of death (HR, 0.57; 95% CI, 0.34\u20100.97). Changing the fractionation from conventional to accelerated did not achieve any benefit but incurred higher toxicities (acute mucositis and dehydration).<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS<\/jats:title><jats:p>Preliminary results indicate that the benefit of changing to an induction\u2010concurrent sequence remains uncertain; replacing fluorouracil with oral capecitabine warrants further validation in view of its convenience, favorable toxicity profile, and favorable trends in efficacy; and accelerated fractionation is not recommended for patients with locoregionally advanced NPC who receive chemoradiotherapy. <jats:bold><jats:italic>Cancer<\/jats:italic> 2015;121:1328\u20131338.<\/jats:bold> \u00a9 <jats:italic>2014 American Cancer Society<\/jats:italic>.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.29208","type":"journal-article","created":{"date-parts":[[2014,12,19]],"date-time":"2014-12-19T23:35:25Z","timestamp":1419032125000},"page":"1328-1338","source":"Crossref","is-referenced-by-count":151,"title":["Preliminary results of trial NPC\u20100501 evaluating the therapeutic gain by changing from concurrent\u2010adjuvant to induction\u2010concurrent chemoradiotherapy, changing from fluorouracil to capecitabine, and changing from conventional to accelerated radiotherapy fractionation in patients with locoregionally advanced nasopharyngeal carcinoma"],"prefix":"10.1002","volume":"121","author":[{"given":"Anne W.M.","family":"Lee","sequence":"first","affiliation":[{"name":"Department of Clinical Oncology Pamela Youde Nethersole Eastern Hospital Hong Kong China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger K.C.","family":"Ngan","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology Queen Elizabeth Hospital Hong Kong China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stewart Y.","family":"Tung","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology Tuen Mun Hospital Hong Kong China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology Princess Margaret Hospital Hong Kong China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dora L.W.","family":"Kwong","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, Queen Mary Hospital University of Hong Kong Hong Kong China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tai\u2010Xiang","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology Sun Yat Sen University Cancer Center Guangzhou, Guangdong China, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony T.C.","family":"Chan","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology Prince of Wales Hospital, Chinese University of Hong Kong Hong Kong China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy L.K.","family":"Chan","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology Pamela Youde Nethersole Eastern Hospital Hong Kong China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry","family":"Yiu","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology Queen Elizabeth Hospital Hong Kong China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wai\u2010Tong","family":"Ng","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology Pamela Youde Nethersole Eastern Hospital Hong Kong China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Wong","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology Tuen Mun Hospital Hong Kong China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kam\u2010Tong","family":"Yuen","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology Princess Margaret Hospital Hong Kong China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Yau","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology Queen Elizabeth Hospital Hong Kong China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Foon\u2010Yiu","family":"Cheung","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology Queen Elizabeth Hospital Hong Kong China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oscar S.H.","family":"Chan","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology Pamela Youde Nethersole Eastern Hospital Hong Kong China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Horace","family":"Choi","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology School of Public Health University of Hong Kong Hong Kong China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rick","family":"Chappell","sequence":"additional","affiliation":[{"name":"Department of Biostatistics University of Wisconsin Medical School Madison Wisconsin"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,12,19]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.4.1310"},{"key":"e_1_2_7_3_1","unstructured":"National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology\u2010Head and Neck Cancers version 2.2014. Available at:http:\/\/www.nccn.org\/professionals\/physician_gls\/f_guidelines.asp#head\u2010and\u2010neck. Accessed June 24 2014."},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.16.790"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djq258"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.28049"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2010.10.026"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2010.09.023"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2008.02.003"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.07.011"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds266"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(00)00444-5"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.8.2282"},{"key":"e_1_2_7_14_1","doi-asserted-by":"crossref","first-page":"4097","DOI":"10.1200\/JCO.2001.19.21.4097","article-title":"Oral capecitabine compared with intravenous 5\u2010fluorouracil plus leucovorin (Mayo Clinic regimen) in patients with metastatic colorectal cancer: results of a large phase III study","volume":"19","author":"Cutsem E","year":"2001","journal-title":"J Clin Oncol"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdr366"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdr031"},{"issue":"9","key":"e_1_2_7_17_1","first-page":"68","article-title":"UFT and its metabolites inhibit cancer\u2010induced angiogenesis via a VEGF\u2010related pathway","volume":"10","author":"Basaki Y","year":"2000","journal-title":"Oncol"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4757-3656-4"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13566-012-0032-0"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2005.06.037"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70320-5"},{"issue":"5","key":"e_1_2_7_22_1","article-title":"Meta\u2010analysis of chemotherapy in nasopharyngeal carcinoma (MAC\u2010NPC): an update on 4,806 patients [abstract]","volume":"32","author":"Blanchard P","year":"2014","journal-title":"J Clin Oncol"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.18.1545"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdr116"},{"issue":"5","key":"e_1_2_7_25_1","article-title":"Randomized phase III trial of concurrent chemoradiation with or without neoadjuvant gemcitabine, carboplatin, and paclitaxel in locally advanced nasopharyngeal cancer [abstract]","volume":"32","author":"Tan T","year":"2014","journal-title":"J Clin Oncol"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1368-8375(02)00120-3"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)69121-6"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70346-1"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0912217"}],"updated-by":[{"DOI":"10.1002\/cncr.32577","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2019,10,22]],"date-time":"2019-10-22T00:00:00Z","timestamp":1571702400000}}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.29208","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.29208","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T21:09:33Z","timestamp":1760303373000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.29208"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12,19]]},"references-count":28,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2015,4,15]]}},"alternative-id":["10.1002\/cncr.29208"],"URL":"https:\/\/doi.org\/10.1002\/cncr.29208","archive":["Portico"],"relation":{"erratum":[{"id-type":"doi","id":"10.1002\/cncr.32577","asserted-by":"object"}]},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,12,19]]}}}